BOSTON — CorePlus Servicios Clínicos y Patológicos and Ibex Medical Analytics said they have expanded their partnership with the clinical deployment of an artificial intelligence-powered diagnostic solution for transurethral resection of the prostate procedures.
The companies announced the rollout of Ibex Prostate for TURP within a lab-developed test workflow, marking a new step in integrating AI into routine clinical pathology. The system is designed to support pathologists by enabling faster and more accurate analysis of high-volume tissue samples.
CorePlus said it has now surpassed 250,000 AI-based diagnostic analyses in routine clinical use using the Ibex platform, a milestone that highlights one of the largest real-world deployments of AI in digital pathology.
TURP cases can be particularly challenging for pathologists due to the need to review large volumes of tissue while detecting small malignant areas. The Ibex Prostate system provides case-level AI findings to help triage samples, flag high-priority slides, and highlight regions of interest for further review.
“TURP specimens represent one of the most challenging diagnostic scenarios in pathology, where high volume and low cancer prevalence demand both efficiency and precision,” said Mariano de Socarraz, CEO of CorePlus. “Our commitment at CorePlus is to lead the transformation toward precision pathology, where advanced technologies enable more accurate, consistent, and clinically actionable diagnoses. By integrating Ibex Prostate for TURP into our workflow, we are strengthening our ability to deliver the highest standard of care for patients undergoing prostate cancer evaluation.”
The deployment builds on CorePlus’s earlier work integrating AI into prostate and breast biopsy diagnostics and its publication of research on AI-driven diagnostic accuracy. The companies said the latest expansion aims to address growing global demand for faster and more precise cancer diagnostics.
“Our collaboration with CorePlus demonstrates how AI can be successfully integrated into routine clinical practice at scale,” said Yair Heller, CEO of Ibex Medical Analytics. “CorePlus’s extensive experience makes them an ideal partner for the deployment of Ibex Prostate for TURP, bringing advanced diagnostic tools to patients undergoing these critical procedures.”
The announcement coincides with the USCAP 2026 Annual Meeting, where CorePlus is being recognized for its contributions to digital pathology and the adoption of AI-driven diagnostics.
